2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
189
Neoplasm Metastasis
24
Neoplasms
23
Ovarian Neoplasms
12
Sarcoma
10
Pancreatic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Melanoma
7
Endometrial Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Prostatic Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Head and Neck Neoplasms
6
Carcinoma, Renal Cell
6
Breast Diseases
6
Recurrence
5
Medulloblastoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Triple Negative Breast Neoplasms
4
Sarcoma, Ewing
4
Neoplasms by Site
4
Lymphoma, Mantle-Cell
4
Liposarcoma
4
Glioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
Cyclophosphamide
14
fludarabine
9
fludarabine phosphate
8
Busulfan
5
Bendamustine Hydrochloride
5
Tacrolimus
4
Rituximab
4
Mycophenolic Acid
4
ibrutinib
3
Melphalan
3
Bortezomib
3
AP 1903 reagent
3
tetulomab tetraxetan lu-177
2
ponatinib
2
pembrolizumab
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Lutetium
2
Etoposide
2
Doxorubicin
2
Brentuximab Vedotin
2
Bone Marrow Transplantation
2
thymoglobulin
1
pimonidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immune System Diseases
×
palbociclib
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled